141 related articles for article (PubMed ID: 38146568)
1. Demographics, Characteristics, and Outcomes of Male Breast Cancer Patients at the Methodist Health System, Dallas, USA.
Nong HQ; Eastwood D; Rodriguez K; Puri V
Cureus; 2023 Nov; 15(11):e49394. PubMed ID: 38146568
[TBL] [Abstract][Full Text] [Related]
2. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
[TBL] [Abstract][Full Text] [Related]
3. Male Breast Cancer and Hyperestrogenemia: A Thirteen-Year Review.
Tariq KB; Al-Saffar F; Ibrahim S; Pham D; Farhangi A; Rana F; Zaiden R
World J Oncol; 2014 Apr; 5(2):55-61. PubMed ID: 29147378
[TBL] [Abstract][Full Text] [Related]
4. Real-World Tumor Response of Palbociclib in Combination With an Aromatase Inhibitor as First-Line Therapy in Pre/Perimenopausal Women With Metastatic Breast Cancer.
DeMichele A; Robert N; Chen C; Kim S; Zhang Z; Lu DR; Aguilar KM; Wang Y; Li B; Schneeweiss S; Rassen JA; Gaffney M; McRoy L
Target Oncol; 2023 Jul; 18(4):543-558. PubMed ID: 37428347
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes and metastatic behavior between de novo versus recurrent HER2-positive metastatic breast cancer: A 17-year single-institution cohort study at Taipei Veterans General Hospital.
Cheng HF; Tsai YF; Huang CC; Lien PJ; Wang YL; Hsu CY; Chen YJ; Liu CY; Chao TC; Lin YS; Feng CJ; Chiu JH; Chau GY; Tseng LM
J Chin Med Assoc; 2022 Jan; 85(1):88-94. PubMed ID: 34561409
[TBL] [Abstract][Full Text] [Related]
6. Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2- Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy.
Hao Y; Li N; Fang AP; Koo V; Peeples M; Kageleiry A; Wu EQ; Guérin A
Adv Ther; 2016 Jun; 33(6):983-97. PubMed ID: 27216253
[TBL] [Abstract][Full Text] [Related]
7. Clinical Outcomes, Treatment Patterns, and Health Resource Utilization Among Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutation: A Real-World Retrospective Study.
Quek RGW; Mardekian J
Adv Ther; 2019 Mar; 36(3):708-720. PubMed ID: 30656571
[TBL] [Abstract][Full Text] [Related]
8. The ongoing French metastatic breast cancer (MBC) cohort: the example-based methodology of the Epidemiological Strategy and Medical Economics (ESME).
Pérol D; Robain M; Arveux P; Mathoulin-Pélissier S; Chamorey E; Asselain B; Berchery D; Gourgou S; Breton M; Delaine-Clisant S; Mons M; Diéras V; Carton M; Guizard AV; Laborde L; Laurent C; Loeb A; Mouret-Reynier MA; Parent D; Perrocheau G; Campion L; Velten M; Cailliot C; Ezzalfani M; Simon G
BMJ Open; 2019 Feb; 9(2):e023568. PubMed ID: 30796119
[TBL] [Abstract][Full Text] [Related]
9. Characterization of Korean Male Breast Cancer Using an Online Nationwide Breast-Cancer Database: Matched-Pair Analysis of Patients With Female Breast Cancer.
Choi MY; Lee SK; Lee JE; Park HS; Lim ST; Jung Y; Ko BK; Nam SJ;
Medicine (Baltimore); 2016 Apr; 95(16):e3299. PubMed ID: 27100414
[TBL] [Abstract][Full Text] [Related]
10. De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry.
Tripathy D; Brufsky A; Cobleigh M; Jahanzeb M; Kaufman PA; Mason G; O'Shaughnessy J; Rugo HS; Swain SM; Yardley DA; Chu L; Li H; Antao V; Hurvitz SA
Oncologist; 2020 Feb; 25(2):e214-e222. PubMed ID: 32043771
[TBL] [Abstract][Full Text] [Related]
11. Patient-reported Quality of Life and Treatment Satisfaction in Patients With HR
Wood R; Mitra D; de Courcy J; Iyer S
Clin Ther; 2017 Aug; 39(8):1719-1728. PubMed ID: 28751098
[TBL] [Abstract][Full Text] [Related]
12. Metaplastic breast carcinoma: clinical-pathologic characteristics and HER2/neu expression.
Barnes PJ; Boutilier R; Chiasson D; Rayson D
Breast Cancer Res Treat; 2005 May; 91(2):173-8. PubMed ID: 15868445
[TBL] [Abstract][Full Text] [Related]
13. The impact of new systemic therapies on survival and time on hormonal treatment in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: A population-based study in British Columbia from 2003 to 2013.
Le D; Speers C; Thompson L; Gondara L; Nichol A; Lohrisch C
Cancer; 2020 Mar; 126(5):971-977. PubMed ID: 31750938
[TBL] [Abstract][Full Text] [Related]
14. Treatment Sequencing Patterns and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021.
Jaber Chehayeb R; Hood A; Wang X; Miksad R; Schellhorn Mougalian S; Lustberg MB; Wang SY; Greenup RA; Pusztai L; Kunst N
JAMA Netw Open; 2022 Nov; 5(11):e2244204. PubMed ID: 36445704
[TBL] [Abstract][Full Text] [Related]
15. Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice.
Brufsky A; Liu X; Li B; McRoy L; Layman RM
Target Oncol; 2021 Sep; 16(5):601-611. PubMed ID: 34338965
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy or endocrine therapy, first-line treatment for patients with hormone receptor-positive HER2-negative metastatic breast cancer in China: a real-world study.
Yuan Y; Zhang S; Yan M; Yin Y; Song Y; Jiang Z
Ann Transl Med; 2021 May; 9(10):831. PubMed ID: 34164465
[TBL] [Abstract][Full Text] [Related]
17. Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world database.
Courtinard C; Gourgou S; Jacot W; Carton M; Guérin O; Vacher L; Bertaut A; Le Deley MC; Pérol D; Marino P; Levy C; Uwer L; Perrocheau G; Schiappa R; Bachelot F; Parent D; Breton M; Petit T; Filleron T; Loeb A; Pélissier SM; Robain M; Delaloge S; Bellera C
BMC Med; 2023 Mar; 21(1):87. PubMed ID: 36882736
[TBL] [Abstract][Full Text] [Related]
18. Male Breast Cancer: Surgical and Genetic Features and a Multidisciplinary Management Strategy.
Pellini F; Granuzzo E; Urbani S; Mirandola S; Caldana M; Lombardi D; Fiorio E; Mandarà M; Pollini GP
Breast Care (Basel); 2020 Feb; 15(1):14-20. PubMed ID: 32231493
[TBL] [Abstract][Full Text] [Related]
19. Metastatic breast cancer in young women: a population-based cohort study to describe risk and prognosis.
Tjokrowidjaja A; Lee CK; Houssami N; Lord S
Intern Med J; 2014 Aug; 44(8):764-70. PubMed ID: 24863750
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry.
Zell JA; Tsang WY; Taylor TH; Mehta RS; Anton-Culver H
Breast Cancer Res; 2009; 11(1):R9. PubMed ID: 19228416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
